Stock CLSD CLEARSIDE BIOMEDICAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Clearside Biomedical, Inc.

Equities

CLSD

US1850631045

Real-time Estimate Cboe BZX
Other stock markets
 03:58:27 2024-04-18 pm EDT 		5-day change 1st Jan Change
1.33 USD +5.56% Intraday chart for Clearside Biomedical, Inc. +2.31% +13.68%
Apr. 16 Clearside Biomedical, Inc Appoints Anthony S. Gibney to its Board of Directors CI
Mar. 18 Clearside Biomedical Names Victor Chong Chief Medical Officer MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
AQ
Clearside Biomedical, Inc Appoints Anthony S. Gibney to its Board of Directors
CI
Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
AQ
Clearside Biomedical Names Victor Chong Chief Medical Officer
MT
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
AQ
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
CI
Wedbush Trims Clearside Biomedical's PT to $4 From $5 After Increased Share Count, Model Adjustments; Maintains Outperform Rating
MT
Clearside Biomedical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Transcript : Clearside Biomedical, Inc., Q4 2023 Earnings Call, Mar 12, 2024
Clearside Biomedical, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
AQ
Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024
AQ
Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering
AQ
Clearside Biomedical Shares Decline After Stock Sale by CEO, CFO
MT
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
AQ
Clearside Biomedical, Inc. Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
CI
Transcript : Clearside Biomedical, Inc., Q3 2023 Earnings Call, Nov 13, 2023
Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
AQ
Clearside Biomedical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CLSD Stock
  4. News Clearside Biomedical, Inc.